Sino Biopharmaceutical (HK:1177) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sino Biopharmaceutical has received approval from China’s National Medical Products Administration for its Benmelstobart Injection, in combination with Anlotinib Hydrochloride Capsule, to treat recurrent or metastatic endometrial cancer. This marks the second approval for Benmelstobart and the seventh for Anlotinib, highlighting significant potential in addressing unmet needs for patients with limited treatment options. The company’s commitment to advancing innovative therapies continues with ongoing Phase III trials for various cancers.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.